Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This research paper reviews the mechanisms and management of non-biologic immunosuppressive drugs used in dermatology, highlighting their safety profiles and handling during pregnancy, breastfeeding, and vaccination, but does not report specific results on these aspects.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

This paper discusses the challenges of diagnosing drug eruptions, emphasizing the nonspecific patterns and unclear pathomechanisms, and calls for further research using new biologic drugs to understand these reactions better.

This review outlines the changing landscape of psoriasis vulgaris treatment with biologics, which offer benefits but also have increasingly recognized adverse effects, without presenting new clinical results.

This review highlights novel drug delivery systems for alopecia that enhance localization in the pilosebaceous unit, reduce systemic exposure, and support sustained drug release, with a focus on optimized follicular carriers ranging from 100-300 nm for improved drug residence compared to conventional methods.

This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.

This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.

This study highlights that while advances in dermatology, such as biologics and JAK inhibitors, have improved treatments for conditions like atopic dermatitis and psoriasis, challenges remain, including issues with lasting efficacy and the need for more personalized therapies.

This review highlights the ongoing need for novel treatments for autosomal recessive congenital ichthyoses, suggesting that drug repositioning, utilizing existing medications or biologics, could provide more affordable and effective options for managing this lifelong skin condition.

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

In this study, researchers explored drug repurposing as a potential strategy for treating psoriasis and identified Pioglitazone, Trimipramine, and Dimetindene as promising candidates for this indication, based on molecular docking and predictive algorithms.

This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.

This study reports two cases of alopecia associated with anti-TNF therapy, highlighting a new entity combining features of alopecia areata and psoriatic alopecia.

This guideline outlines therapies for hidradenitis suppurativa/acne inversa, noting that oral tetracyclines, clindamycin, and surgical options are important for treatment, with adalimumab, secukinumab, and bimekizumab also approved.

This review highlights recent advances in pediatric dermatologic treatments, including the use of propranolol for infantile hemangiomas and etanercept for plaque psoriasis, but it reports no new clinical results.

This study reports that a lower 2D:4D finger length ratio is significantly associated with higher disease activity and reduced spinal mobility in females with ankylosing spondylitis, but not in males.

This review explores the efficacy and safety of treatments for dissecting cellulitis of the scalp, revealing a predominance of case reports and series, and concludes that randomized controlled trials are needed for better evidence-based therapies.

This review discusses various treatment options for Alopecia Areata, focusing on both medical and psychological approaches, and reports no new clinical results.

This paper reviews the differential diagnoses and diagnostic tests to distinguish alopecia areata from other types of hair loss, without providing new clinical findings.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

In this case report, a 67-year-old woman experienced patchy hair loss, likely related to denosumab treatment for osteoporosis, as other potential causes were ruled out; stopping denosumab led to hair regrowth following intralesional triamcinolone treatment, suggesting a potential denosumab-induced alopecia areata.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This article outlines manifestations of systemic lupus erythematosus, noting rapid joint symptom improvement with corticosteroids and antimalarial drug responsiveness for skin symptoms, and links anti-Ro with photosensitive rash and subacute lupus.

This article reviews the clinical presentation, diagnosis, and treatment options for discoid lupus erythematosus and reports no new clinical results.

This study reported that dupilumab led to significant reduction in skin rash severity and complete hair regrowth in an 11-year-old boy with severe alopecia areata and atopic dermatitis.

This review explores multidisciplinary advances in understanding alopecia areata, including epidemiology, pathogenesis, and innovative treatments, but reports no new research results.

This study observed that dermatological patients using certain immunosuppressants, like azathioprine and high-dose prednisolone, had a reduced humoral immune response to the Sinovac-CoronaVac COVID-19 vaccine compared to those without such treatments.